Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 1.00 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.65 |
| ▸ | NOD1 | Q9Y239 | 7/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.43 |
| ▸ | GRM8 | O00222 | 1/20 | 0.43 |
| ▸ | GRM6 | O15303 | 1/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | GSR | P00390 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.43 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glutathione SCHEMBL28505216 | 1.00 | PTGS1 (1.00) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| Glutathione SCHEMBL14364095 | 1.00 | PTGS1 (1.00) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| Glutathione SCHEMBL272141 | 1.00 | PTGS1 (1.00) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| Glutathione SCHEMBL5167025 | 1.00 | PTGS1 (1.00) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| Glutathione SCHEMBL13105609 | 1.00 | PTGS1 (1.00) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| Glutathione SCHEMBL7469803 | 1.00 | PTGS1 (1.00) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| Glutathione SCHEMBL9167 | 1.00 | PTGS1 (1.00) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| Glutathione SCHEMBL15701576 | 1.00 | PTGS1 (1.00) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| Glutathione SCHEMBL1105665 | 1.00 | PTGS1 (1.00) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| Glutathione SCHEMBL30733475 | 1.00 | PTGS1 (1.00) | PTGS1GSTK1GLO1NOD1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014143383-A1 | TRANSPOSOME TETHERED TO A GENE DELIVERY VEHICLE | AGILENT TECHNOLOGIES, INC. (US) | 2014-09-18 | — | — | WO | claimed |
| EP-0869809-B1 | OXIDIZED GLUTATHIONE AS CYTOKINE AND HEMOPOIETIC FACTOR ENDOGENOUS PRODUCTION ENHANCER | NOVELOS THERAPEUTICS INC (US) | 2002-03-27 | — | — | EP | claimed |
| CN-122005845-A | Targeting nanoparticle for breast cancer treatment and preparation and application thereof | 中国人民解放军空军军医大学 | 2026-05-12 | — | — | CN | disclosed |
| US-20260078173-A1 | SINGLE-CHAIN ZAGOTENEMAB ANTIBODY-TRANSFERRIN FUSION PROTEIN FOR ENHANCED EFFICACY AND INDICATIONS | RNA THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260078174-A1 | SINGLE-CHAIN MEDI1341 ANTIBODY-TRANSFERRIN FUSION PROTEIN FOR ENHANCED EFFICACY AND INDICATIONS | RNA THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260071004-A1 | SINGLE-CHAIN TRASTUZUMAB ANTIBODY-TRANSFERRIN FUSION PROTEIN FOR ENHANCED EFFICACY AND INDICATIONS | RNA THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260070968-A1 | SINGLE-CHAIN USTEKINUMAB ANTIBODY-TRANSFERRIN FUSION PROTEIN FOR ENHANCED EFFICACY AND INDICATIONS | RNA THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4469560-B1 | AN IMPROVED CELL CULTURE MEDIUM FOR CRUSTACEAN CELLS | UNIV GENT (BE) | 2026-03-11 | — | — | EP | disclosed |
| US-20260062489-A1 | SINGLE-CHAIN TEPROTUMUMAB ANTIBODY-TRANSFERRIN FUSION PROTEIN FOR ENHANCED EFFICACY AND INDICATIONS | RNA THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260062473-A1 | SINGLE-CHAIN TILDRAKIZUMAB ANTIBODY-TRANSFERRIN FUSION PROTEIN FOR ENHANCED EFFICACY AND INDICATIONS | RNA THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260062467-A1 | SINGLE-CHAIN SOLANEZUMAB ANTIBODY-TRANSFERRIN FUSION PROTEIN FOR ENHANCED EFFICACY AND INDICATIONS | RNA THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-5220035-A | Test compositions which generate different hues at different analyte concentrations | MILES INC. (US) | 1993-06-15 | — | — | US | disclosed |
| US-5190863-A | Composition for determining the presence or concentration of D-β-hydroxybutyrate | MILES INC. (US) | 1993-03-02 | — | — | US | disclosed |
| EP-0438386-A4 | NOVEL IMPROVERS FOR FLOUR AND YEAST RAISED BAKED GOODS | — | 1991-09-11 | — | — | EP | disclosed |
| US-5041658-A | Indicator generates a variety of hues depending on the analyte concentration | MILES INC. (US) | 1991-08-20 | — | — | US | disclosed |
| EP-0438386-A1 | NOVEL IMPROVERS FOR FLOUR AND YEAST RAISED BAKED GOODS | GEORGE WESTON FOODS LIMITED (AU) | 1991-07-31 | — | — | EP | disclosed |
| US-4988517-A | ANTITUMOR AGENTS, BENZYLSELENOCYANATE, INCREASING GLUTATHIONE PEROXIDASE | AMERICAN HEALTH FOUNDATION (US) | 1991-01-29 | — | — | US | disclosed |
| US-4975367-A | Catalytic test composition intended to produce a range of colors | MILES INC. (US) | 1990-12-04 | — | — | US | disclosed |
| US-4898813-A | Catalytic test composition intended to produce a range of colors | MILES INC. | 1990-02-06 | — | — | US | disclosed |
| WO-1988003365-A1 | NOVEL IMPROVERS FOR FLOUR AND YEAST RAISED BAKED GOODS | GEORGE WESTON FOODS LIMITED (AU) | 1988-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260071004-A1 | SINGLE-CHAIN TRASTUZUMAB ANTIBODY-TRANSFERRIN FUSION PROTEIN FOR ENHANCED EFFICACY AND INDICATIONS | CD4, TFRC, VAMP8 | PTGS1 4692/4885GSTK1 2591/4885GLO1 3901/4885 |
| US-20260070968-A1 | SINGLE-CHAIN USTEKINUMAB ANTIBODY-TRANSFERRIN FUSION PROTEIN FOR ENHANCED EFFICACY AND INDICATIONS | CD4, CD47, TFRC | PTGS1 3952/4885GSTK1 2959/4885GLO1 4119/4885 |
| US-20260062489-A1 | SINGLE-CHAIN TEPROTUMUMAB ANTIBODY-TRANSFERRIN FUSION PROTEIN FOR ENHANCED EFFICACY AND INDICATIONS | CD4, TFRC, VAMP8 | PTGS1 4627/4885GSTK1 2503/4885GLO1 3250/4885 |
| US-20260062473-A1 | SINGLE-CHAIN TILDRAKIZUMAB ANTIBODY-TRANSFERRIN FUSION PROTEIN FOR ENHANCED EFFICACY AND INDICATIONS | CD4, TFRC, VAMP8 | PTGS1 4737/4885GSTK1 2330/4885GLO1 3896/4885 |
| US-20260078174-A1 | SINGLE-CHAIN MEDI1341 ANTIBODY-TRANSFERRIN FUSION PROTEIN FOR ENHANCED EFFICACY AND INDICATIONS | TFRC, CD4, FCGR3B | PTGS1 4647/4885GSTK1 1773/4885GLO1 3014/4885 |
| US-20260062467-A1 | SINGLE-CHAIN SOLANEZUMAB ANTIBODY-TRANSFERRIN FUSION PROTEIN FOR ENHANCED EFFICACY AND INDICATIONS | CD4, TFRC, VAMP8 | PTGS1 4654/4885GSTK1 2972/4885GLO1 3059/4885 |
| US-20260078173-A1 | SINGLE-CHAIN ZAGOTENEMAB ANTIBODY-TRANSFERRIN FUSION PROTEIN FOR ENHANCED EFFICACY AND INDICATIONS | CD4, TFRC, FCGR3B | PTGS1 4417/4885GSTK1 2420/4885GLO1 4018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.